| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-01-08 | AP611074 | condyloma (ano-genital warts) |
2a | Anaconda Pharma (France) | Infectious diseases |
| 2014-01-08 | Oxabact® (Oxalobacter formigenes strain HC-1) | primary hyperoxaluria | 1 | OxThera (Sweden) | Rare diseases |
| 2014-01-07 | ALKS 5461 | major depressive disorder (MDD) | 3 | Alkermes (Ireland) | CNS diseases - Mental diseases |
| 2014-01-02 | CER-001 | secondary prevention of cardiovascular events in patients with acute coronary syndrome | 2 | Cerenis Therapeutics (France) | Cardiovascular diseases |
| 2014-01-02 | Traumakine® - FP-1201 (human recombinant interferon-beta 1a) | acute lung injury (ALI) , acute respiratory distress syndrome (ARDS) | 1-2 | Faron Pharmaceuticals (Finland) | Lung diseases - Respiratory diseases |
| 2013-12-30 | veliparib (ABT-888) | triple-negative breast cancer (TNBC) | 3 | Abbvie (USA - IL) | Cancer - Oncology |
| 2013-12-27 | AXL1717 | non small cell lung cancer (NSLC) | 2 | Axelar (Sweden) | Cancer - Oncology |
| 2013-12-20 | NGR-hTNF | first line maintenance treatment of pleural mesothelioma |
2 | MolMed (Italy) | Cancer - Oncology |
| 2013-12-18 | Octagam 5% | relapsing multiple sclerosis | 2-3 | Octapharma (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-12-18 | biosimilar version of Humira® (adalimumab) | psoriasis | 3 | Sandoz (Switzerland) | Allergic diseases - Inflammatory diseases - Dermatological diseases |
| 2013-12-17 | 2B3-201 | 1 | to-BBB (The Netherlands) | CNS diseases - Neurodegenerative diseases - Cancer - Oncology - Neuroinflammatory diseases | |
| 2013-12-17 | inhaled form of Lynovex | cystic fibrosis |
preclinical | NovaBiotics (UK) | Rare diseases - Genetic diseases |
| 2013-12-16 | CV9104 | castration-resistant prostate cancer. | 2b | CureVac (Germany) | Cancer - Oncology |
| 2013-12-13 | lesinurad | gout | 3 | AstraZeneca (UK) | Inflammatory diseases |
| 2013-12-12 | simeprevir, TMC647055 and JNJ56914845 | hepatitis C | 2a | Medivir (Sweden) | Infectious diseases |
| 2013-12-10 | NY-ESO-1c259-T cell therapy product | multiple myeloma | 1-2 | Adaptimmune (UK) | Cancer - Oncology |
| 2013-12-10 | indatuximab ravtansine (BT-062) | multiple myeloma | 1-2a | Biotest (Germany) | Cancer - Oncology |
| 2013-12-10 | MOR208 in combination with lenalidomide (Revlimid®) | chronic lymphocytic leukemia (CLL) |
2 | Morphosys (Germany) | Cancer - Oncology |
| 2013-12-10 | NYESO-1c259-T cell therapy product | multiple myeloma | 1-2a | Adaptimmune (UK) | Cancer - Oncology |
| 2013-12-07 | CTL019 (tisagenlecleucel-T) | chronic lymphocytic leukemia (CLL) | Novartis (Switzerland) | Cancer - Oncology |
